Impact of competition on reimbursement decisions for cancer drugs in China: an observational study
H Guan, Y Shi, J Song, M Cao, A Sun, S Liu… - The Lancet Regional …, 2024 - thelancet.com
Summary Background Annual Chinese National negotiations for including innovative drugs
in the National Reimbursement Drug List (NRDL) reveal an increasing number of new drugs …
in the National Reimbursement Drug List (NRDL) reveal an increasing number of new drugs …
[HTML][HTML] Financial toxicity of informal caregivers of colorectal cancer patients: A cross-sectional study
M Zhang, X Wang, M Shao, T Li, S Guo, Y Yang… - European Journal of …, 2024 - Elsevier
Purpose To assess the level of financial toxicity of informal caregivers of colorectal cancer
patients and explore the related key influencing factors. Method A descriptive survey design …
patients and explore the related key influencing factors. Method A descriptive survey design …
Systematic review of the impact of the National Medication Price Negotiated Policy on the accessibility of drugs in China, 2016–2024
N Peng, C Du, Y Gong, X Long, C Wang, P Liu - BMJ open, 2024 - bmjopen.bmj.com
Objective To alleviate the economic burden of innovative drugs on patients in China, the
government has been negotiating drug prices since 2016 to enhance their accessibility. This …
government has been negotiating drug prices since 2016 to enhance their accessibility. This …
The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data
BX Li, YQ Wang, YY Yi, N Zhou, ZX Lv, R Ma, X Li… - BMC Public Health, 2024 - Springer
Abstract Background The National Drug Price Negotiation (NDPN) policy has entered a
normalisation stage, aiming to alleviate, to some extent, the disease-related and economic …
normalisation stage, aiming to alleviate, to some extent, the disease-related and economic …
[HTML][HTML] The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China
Y Bao, Y Liu, R Ma, P Zhang, X Li - Journal of Global Health, 2023 - ncbi.nlm.nih.gov
Background The high costs of novel anticancer drugs have caused concern among
healthcare stakeholders. To address the knowledge gap on the proportion of survival benefit …
healthcare stakeholders. To address the knowledge gap on the proportion of survival benefit …
Current situation and capacity of cancer diagnosis and treatment in county hospitals in China: a multicenter cross-sectional survey
Y Wang, T Sun, Z He, Z Liu, S Zheng, Z Yan… - Holistic Integrative …, 2024 - Springer
Purpose County-level hospitals in China constitute a vital component of the healthcare
system, delivering essential medical services, emergency care, and specialized treatments …
system, delivering essential medical services, emergency care, and specialized treatments …